These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32975901)

  • 1. Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis.
    Lenfant L; Cancel-Tassin G; Gazut S; Compérat E; Rouprêt M; Cussenot O
    BJU Int; 2021 Mar; 127(3):375-383. PubMed ID: 32975901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer.
    Lipunova N; Wesselius A; Cheng KK; van Schooten FJ; Bryan RT; Cazier JB; Galesloot TE; Kiemeney LALM; Zeegers MP
    Eur Urol Oncol; 2019 Jul; 2(4):381-389. PubMed ID: 31277774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
    Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of oncostatin M receptor gene polymorphisms in bladder cancer.
    Deng S; He SY; Zhao P; Zhang P
    World J Surg Oncol; 2019 Feb; 17(1):30. PubMed ID: 30755233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer.
    Chen M; Hildebrandt MA; Clague J; Kamat AM; Picornell A; Chang J; Zhang X; Izzo J; Yang H; Lin J; Gu J; Chanock S; Kogevinas M; Rothman N; Silverman DT; Garcia-Closas M; Grossman HB; Dinney CP; Malats N; Wu X
    Cancer Prev Res (Phila); 2010 Oct; 3(10):1235-45. PubMed ID: 20858759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer.
    Lee EK; Ye Y; Kamat AM; Wu X
    Cancer; 2013 May; 119(9):1643-51. PubMed ID: 23529717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
    Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    Lacombe L; Fradet V; Lévesque É; Pouliot F; Larue H; Bergeron A; Hovington H; Caron A; Nguile-Makao M; Harvey M; Fradet Y; Guillemette C
    Cancer Prev Res (Phila); 2016 Feb; 9(2):189-95. PubMed ID: 26645279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment.
    Masson-Lecomte A; López de Maturana E; Goddard ME; Picornell A; Rava M; González-Neira A; Márquez M; Carrato A; Tardon A; Lloreta J; Garcia-Closas M; Silverman D; Rothman N; Kogevinas M; Allory Y; Chanock SJ; Real FX; Malats N;
    Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1144-50. PubMed ID: 27197286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
    Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
    Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.
    Carta A; Pavanello S; Mastrangelo G; Fedeli U; Arici C; Porru S
    Int J Environ Res Public Health; 2018 Jul; 15(8):. PubMed ID: 30042310
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
    Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
    Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.
    Yates DR; Rouprêt M; Drouin SJ; Audouin M; Cancel-Tassin G; Comperat E; Bitker MO; Cussenot O
    World J Urol; 2013 Feb; 31(1):53-9. PubMed ID: 23053209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
    Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
    [No Abstract]   [Full Text] [Related]  

  • 20. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.